Skip to main content
SpringerLink
Log in

Diuretics for Hypertension in Asians

  • Chapter
  • First Online:
Hypertension and Cardiovascular Disease in Asia

Part of the book series: Updates in Hypertension and Cardiovascular Protection ((UHCP))

  • 679 Accesses

Abstract

Diuretics play a key role in hypertension management. These drugs are the least expensive of available antihypertensive agents. Therefore, diuretics are often utilised for initiation of antihypertensive therapy in low-income countries. In India, China and Japan, diuretics are most often used in combination with renin–angiotensin system inhibitors and calcium channel blockers (CCBs) and less often as monotherapy. The dosages of diuretics used in clinical practice are often lower than those recommended by the authorised guidelines. Physicians do this to avoid the side effects of diuretics. However, these side effects can be diagnosed and managed by the treating physicians. Mineralocorticoid receptor antagonists are the best option for add-on antihypertensive therapy in patients with resistant hypertension, but are underutilised due to the risk of hyperkalaemia and cost. Health providers in Asia need to look into ways in which all antihypertensive agents can be used more effectively to achieve effective blood pressure control.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. O’Flaherty M, Buchan I, Capewell S. Contributions of treatment and lifestyle to declining CVD mortality: why have CVD mortality rates declined so much since the 1960s? Heart. 2013;99(3):159–62.

    Article  Google Scholar 

  2. Anand S, Bradshaw C, Prabhakaran D. Prevention and management of CVD in LMICs: why do ethnicity, culture, and context matter? BMC Med. 2020;18(1):7.

    Article  Google Scholar 

  3. Shah SN, Munjal YP, Kamath SA, Wander GS, Mehta N, Mukherjee S, et al. Indian guidelines on hypertension-IV (2019). J Hum Hypertens. 2020;34(11):745–58.

    Article  Google Scholar 

  4. Wang JG. Chinese hypertension guidelines. Pulse (Basel). 2015;3(1):14–20.

    Article  Google Scholar 

  5. Liu J. Highlights of the 2018 Chinese hypertension guidelines. Clin Hypertens. 2020;1(26):8. https://doi.org/10.1186/s40885-020-00141-3.

    Article  Google Scholar 

  6. Lee HY, Park JB. The Korean Society of Hypertension Guidelines for the Management of Hypertension in 2013: its essentials and key points. Pulse (Basel). 2015;3(1):21–8.

    Article  Google Scholar 

  7. Kim Y. The Korea National Health and nutrition examination survey (KNHANES): current status and challenges. Epidemiol Health. 2014;30(36):e2014002. PMID: 24839580; PMCID: PMC4017741. https://doi.org/10.4178/epih/e2014002.

    Article  Google Scholar 

  8. Deedwania PC, et al. Hypertension in south Asians. Chapter B87. In: Hypertension primer. 4th ed.

    Google Scholar 

  9. Shnaimer JA, Gosadi IM. Primary health care physicians’ knowledge and adherence regarding hypertension management guidelines in southwest of Saudi Arabia. Medicine (Baltimore). 2020;99(17):e19873.

    Article  Google Scholar 

  10. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021–104.

    Article  Google Scholar 

  11. Araoye MA, Chang MY, Khatri IM, Freis ED. Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension. JAMA. 1978;240:1863.

    Article  CAS  Google Scholar 

  12. Finnerty FA Jr, Maxwell MH, Lunn J, Moser M. Long-term effects of furosemide and hydrochlorothiazide in patients with essential hypertension a two-year comparison of efficacy and safety. Angiology. 1977;28:125.

    Article  Google Scholar 

  13. Ernst ME, Carter BL, Basile JN. All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH study into perspective. J Clin Hypertens (Greenwich). 2009 Jan;11(1):5–10.

    Article  CAS  Google Scholar 

  14. Judd E, Calhoun DA. Management of hypertension in CKD: beyond the guidelines. Adv Chronic Kidney Dis. 2015;22(2):116–22.

    Article  Google Scholar 

  15. Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3):S1–87.

    Article  Google Scholar 

  16. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. British Hypertension Society's PATHWAY studies group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–68.

    Article  CAS  Google Scholar 

  17. Whelton PK, Carey RM, Aronow WS, et al. 2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/vASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults. Hypertension. 2018;71:e13–e115.

    CAS  PubMed  Google Scholar 

  18. Gupta R, Sharma KK, Soni S, Gupta N, Khedar RS. Resistant hypertension in clinical practice in India: Jaipur heart watch. J Assoc Physicians India. 2019;67(12):14–7.

    PubMed  Google Scholar 

  19. Pitt B. Mineralocorticoid receptor antagonists for the treatment of hypertension and the metabolic syndrome. Hypertension. 2015;65(1):41–2.

    Article  CAS  Google Scholar 

  20. Taraphder A. Alpha adrenergic blockers in the treatment of hypertension a nephrologist perspective. JAPI. 2014;62:1–5.

    Google Scholar 

  21. Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the working group on cardiovascular pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2018;4(3):180–8.

    Article  Google Scholar 

  22. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

    Article  CAS  Google Scholar 

  23. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Efficacy of vasopressin antagonism in heart failure Outcome study with Tolvaptan (EVEREST) investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome trial. JAMA. 2007;297(12):1319–31.

    Article  CAS  Google Scholar 

  24. Kario K, Chia YC, Sukonthasarn A, Turana Y, Shin J, Chen CH, et al. Diversity of and initiatives for hypertension management in Asia-why we need the HOPE Asia network. J Clin Hypertens (Greenwich). 2020;22(3):331–43.

    Article  Google Scholar 

  25. Lee HY, Shin J, Kim GH, Park S, Ihm SH, Kim HC, et al. 2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Hypertens. 2019;1(25):20.

    Article  Google Scholar 

  26. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42(9):1235–481.

    Article  Google Scholar 

  27. de Brito-Ashurst I, Perry L, Sanders TA, Thomas JE, Dobbie H, Varagunam M, Yaqoob MM. The role of salt intake and salt sensitivity in the management of hypertension in south Asian people with chronic kidney disease: a randomised controlled trial. Heart. 2013;99(17):1256–60.

    Article  Google Scholar 

  28. GenSalt Collaborative Research Group. GenSalt: rationale, design, methods and baseline characteristics of study participants. J Hum Hypertens. 2007;21(8):639–46.

    Article  Google Scholar 

  29. Borah PK, Sharma M, Kalita HC, Pasha MA, Paine SK, Hazarika D, et al. Salt-sensitive phenotypes: a community-based exploratory study from northeastern India. Natl Med J India. 2018;31(3):140–5.

    Article  Google Scholar 

  30. Burnier M, Bakris G, Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? J Hypertens. 2019;37(8):1574–86.

    Article  CAS  Google Scholar 

  31. Firestone MJ, Beasley JM, Kwon SC, Ahn J, Trinh-Shevrin C, Yi SS. Asian American dietary sources of sodium and salt behaviors compared with other racial/ethnic groups, NHANES, 2011-2012. Ethn Dis. 2017;27(3):241.

    Article  Google Scholar 

  32. Johnson C, Santos JA, Sparks E, Raj TS, Mohan S, Garg V, et al. Sources of dietary salt in north and South India estimated from 24 hour dietary recall. Nutrients. 2019;11(2):318.

    Article  Google Scholar 

  33. Anderson CA, Appel LJ, Okuda N, Brown IJ, Chan Q, Zhao L, et al. Dietary sources of sodium in China, Japan, the United Kingdom, and the United States, women and men aged 40 to 59 years: the INTERMAP study. J Am Diet Assoc. 2010;110(5):736–45.

    Article  CAS  Google Scholar 

  34. Miura K, Okuda N, Turin TC, Takashima N, Nakagawa H, Nakamura K, et al. Dietary salt intake and blood pressure in a representative Japanese population: baseline analyses of NIPPON DATA80. J Epidemiol. 2010;20 Suppl 3(Suppl 3):S524–30.

    Article  Google Scholar 

  35. de Lorenzo A, Liaño F. High temperatures and nephrology: the climate change problem. Nefrologia. 2017;37(5):492–500.

    Article  Google Scholar 

  36. Grandjean A. WHO guidelines for drinking-water quality. Geneva: World Health Organization; 2004.

    Google Scholar 

  37. Philip R, Beaney T, Appelbaum N, Gonzalvez CR, Koldeweij C, Golestaneh AK, et al. Variation in hypertension clinical practice guidelines: a global comparison. BMC Med. 2021;19(1):117.

    Article  Google Scholar 

  38. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288(23):2981–97.

    Article  Google Scholar 

  39. Mishra S, Ingole S, Jain R. Salt sensitivity and its implication in clinical practice. Indian Heart J. 2018;70(4):556–64.

    Article  Google Scholar 

  40. Murai K, Obara T, Ohkubo T, Metoki H, Oikawa T, Inoue R, et al. Current usage of diuretics among hypertensive patients in Japan: the Japan home versus office blood pressure measurement evaluation (J-HOME) study. Hypertens Res. 2006;29(11):857–63.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

My grateful thanks to Mr. Ivor Dsouza for transcription and script reading without whom this would not have been possible.

Author information

Authors and Affiliations

  1. Department of Nephrology, Bombay Hospital Institute of Medical Sciences, Mumbai, Maharashtra, India

    Ashok L. Kirpalani & Dilip A. Kirpalani

Authors
  1. Ashok L. Kirpalani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dilip A. Kirpalani
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Apollo Hospitals, Apollo Institute for Blood Pressure Management, Hyderabad, India

    C. Venkata S. Ram

  2. Head, Division of Nephrology Department of Medicine, Yong Loo Lin Sch of Med Natl Univ of Sin, Singapore, Singapore

    Boon Wee Jimmy Teo

  3. Department of Cardiology, Hero DMC Heart Institute, Dayanand Medical College, Ludhiana, Punjab, India

    Gurpreet S. Wander

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kirpalani, A.L., Kirpalani, D.A. (2022). Diuretics for Hypertension in Asians. In: Ram, C.V.S., Teo, B.W.J., Wander, G.S. (eds) Hypertension and Cardiovascular Disease in Asia. Updates in Hypertension and Cardiovascular Protection. Springer, Cham. https://doi.org/10.1007/978-3-030-95734-6_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-95734-6_21

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-95733-9

  • Online ISBN: 978-3-030-95734-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation